JP2022549791A5 - - Google Patents

Info

Publication number
JP2022549791A5
JP2022549791A5 JP2022517738A JP2022517738A JP2022549791A5 JP 2022549791 A5 JP2022549791 A5 JP 2022549791A5 JP 2022517738 A JP2022517738 A JP 2022517738A JP 2022517738 A JP2022517738 A JP 2022517738A JP 2022549791 A5 JP2022549791 A5 JP 2022549791A5
Authority
JP
Japan
Prior art keywords
protein
composition according
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517738A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549791A (ja
Filing date
Publication date
Priority claimed from NL2023863A external-priority patent/NL2023863B1/en
Application filed filed Critical
Publication of JP2022549791A publication Critical patent/JP2022549791A/ja
Publication of JP2022549791A5 publication Critical patent/JP2022549791A5/ja
Pending legal-status Critical Current

Links

JP2022517738A 2019-09-20 2020-09-21 ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用 Pending JP2022549791A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2023863A NL2023863B1 (en) 2019-09-20 2019-09-20 Protein particles and uses thereof
NL2023863 2019-09-20
PCT/AU2020/000107 WO2021051153A1 (en) 2019-09-20 2020-09-21 Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof

Publications (2)

Publication Number Publication Date
JP2022549791A JP2022549791A (ja) 2022-11-29
JP2022549791A5 true JP2022549791A5 (https=) 2023-08-29

Family

ID=68425230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517738A Pending JP2022549791A (ja) 2019-09-20 2020-09-21 ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用

Country Status (7)

Country Link
US (1) US20220378894A1 (https=)
EP (1) EP4031170A4 (https=)
JP (1) JP2022549791A (https=)
CN (1) CN115175696A (https=)
AU (1) AU2020349589A1 (https=)
NL (1) NL2023863B1 (https=)
WO (1) WO2021051153A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109078177B (zh) * 2018-08-09 2022-07-08 安徽智飞龙科马生物制药有限公司 一种预防结核病的疫苗及联合用药物和制备方法、应用
CA3218711A1 (en) * 2021-05-13 2022-11-17 Roee Amit Methods and compositions for treatment of viral infection
CN113801209B (zh) * 2021-11-16 2022-02-11 浙江普康生物技术股份有限公司 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法
CN114835822B (zh) * 2022-04-22 2022-11-04 浙江洪晟生物科技股份有限公司 猪瘟病毒的多聚体疫苗及其制备方法
CN118191298A (zh) * 2022-12-14 2024-06-14 上海索昕生物科技有限公司 一种抗体免疫检测试剂及其制备方法和应用
CN116286682B (zh) * 2022-12-30 2026-04-07 中国农业科学院兰州兽医研究所 O型口蹄疫病毒多表位仿生纳米自组装病毒样颗粒及其制备方法和应用
WO2025106425A1 (en) * 2023-11-13 2025-05-22 University Of Florida Research Foundation, Incorporated Immunogenic composition and uses thereof
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
CN119552230B (zh) * 2024-12-12 2026-03-13 中国人民解放军军事科学院军事医学研究院 一种脂肪酸化修饰的白喉毒素抗原及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
PL196114B1 (pl) * 2002-12-31 2007-12-31 Inst Biotechnologii I Antybiot Ciałka inkluzyjne jako antygeny do doustnej immunizacji zwierząt
CN100999548B (zh) * 2006-01-10 2010-09-08 海南天源康泽医药科技有限公司 白喉毒素突变体crm197及其制备方法
CN102686238A (zh) * 2009-09-09 2012-09-19 马特里瓦克斯研究和开发公司 具有改善的免疫原性的蛋白质基质疫苗
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
KR20130072201A (ko) * 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
IN2012MU00206A (https=) * 2012-01-20 2013-08-09
WO2015134402A1 (en) * 2014-03-03 2015-09-11 Scarab Genomics, Llc Enhanced production of recombinant crm197 in e. coli
KR102730367B1 (ko) 2014-04-15 2024-11-15 그리피스 유니버시티 그룹 a 스트렙토코쿠스 백신
WO2016172762A1 (en) 2015-04-25 2016-11-03 James Cook University Schistosomiasis vaccine
GB201509782D0 (en) 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
BR112019001115A2 (pt) * 2016-07-21 2019-06-25 Vac4All Pte Ltd proteínas de biofusão como vacinas anti-malária
GB201706430D0 (en) 2017-04-24 2017-06-07 Univ Oxford Innovation Ltd Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
KR102893870B1 (ko) 2017-08-23 2025-12-02 그리피스 유니버시티 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
EP3706787A4 (en) * 2017-11-06 2021-10-20 OZQ Pty Ltd VACCINE
CN108159408A (zh) * 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
US12053519B2 (en) * 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen

Similar Documents

Publication Publication Date Title
JP2022549791A5 (https=)
Zhao et al. COVID-19: coronavirus vaccine development updates
US11235052B2 (en) Chikungunya virus RNA vaccines
US12605454B2 (en) Modified virus-like particles of CMV
Denis et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization
Acosta-Coley et al. Vaccines platforms and COVID-19: what you need to know
US20190211065A1 (en) High potency immunogenic compositions
US10905760B2 (en) Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines containing hepatitis B virus genes
JPH01279842A (ja) Ａ型及びｂ型肝炎混合アジュバントワクチン
CN104428312A (zh) 用于登革病毒表位的方法和组合物
Plotkin Six revolutions in vaccinology
CN105473603B (zh) 用于登革病毒疫苗的方法与组合物
JPWO2017122635A1 (ja) 固定化ウイルス粒子を含むワクチン
TW201502136A (zh) 疫苗
EP4161571A2 (en) Chimeric adenoviral vectors
CN102127554B (zh) 一种日本脑炎颗粒疫苗及其制备方法和应用
Chavda et al. History of vaccination
US8691234B2 (en) Vaccine formulation potentiated by the combination of DNA and an antigen
Wu et al. Sub-fragments of the envelope gene are highly protective against the Japanese encephalitis virus lethal infection in DNA priming—protein boosting immunization strategies
WO2025149032A1 (en) Respiratory syncytial virus vaccine compositions and their use
US20230355738A1 (en) Bacteriophage-based, needle and adjuvant-free, mucosal covid-19 vaccine
RU2362586C2 (ru) Фармацевтические композиции для терапевтического применения
Kanizsai Correlation between adverse reactions followed BNT162b2 vaccination against SARS-CoV-2 and the anti-spike protein antibody levels through a 6-month-long follow-up
Lim et al. Development of dengue vaccines
Javadi et al. Synthesis and characterization of physicochemical and immunological properties of recombinant NS3-G2 dendrimer conjugate